You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Details for New Drug Application (NDA): 205266


✉ Email this page to a colleague

« Back to Dashboard


NDA 205266 describes ODOMZO, which is a drug marketed by Sun Pharm and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the ODOMZO profile page.

The generic ingredient in ODOMZO is sonidegib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sonidegib phosphate profile page.
Summary for 205266
Tradename:ODOMZO
Applicant:Sun Pharm
Ingredient:sonidegib phosphate
Patents:3
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 205266
Generic Entry Date for 205266*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 205266
Mechanism of ActionSmoothened Receptor Antagonists
Suppliers and Packaging for NDA: 205266
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ODOMZO sonidegib phosphate CAPSULE;ORAL 205266 NDA Sun Pharmaceutical Industries, Inc. 47335-303 47335-303-15 30 CAPSULE in 1 BOTTLE (47335-303-15)
ODOMZO sonidegib phosphate CAPSULE;ORAL 205266 NDA Sun Pharmaceutical Industries, Inc. 47335-303 47335-303-83 30 CAPSULE in 1 BOTTLE (47335-303-83)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 200MG BASE
Approval Date:Jul 24, 2015TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Mar 30, 2036Product Flag?YSubstance Flag?YDelist Request?
Patent:⤷  Sign UpPatent Expiration:Sep 15, 2029Product Flag?YSubstance Flag?YDelist Request?
Patent:⤷  Sign UpPatent Expiration:Jul 24, 2029Product Flag?Substance Flag?YDelist Request?
Patented Use:TREATMENT OF BASAL CELL CARCINOMA

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.